Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 4
2006 8
2007 8
2008 5
2009 6
2010 3
2011 4
2012 2
2015 2
2016 1
2017 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Early recurrence risk: aromatase inhibitors versus tamoxifen.
Bria E, Carlini P, Cuppone F, Vaccaro V, Milella M, Cognetti F. Bria E, et al. Among authors: cuppone f. Expert Rev Anticancer Ther. 2010 Aug;10(8):1239-53. doi: 10.1586/era.10.54. Expert Rev Anticancer Ther. 2010. PMID: 20735310 Review.
Emerging pathways and future targets for the molecular therapy of pancreatic cancer.
Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Vaccaro V, et al. Among authors: cuppone f. Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Expert Opin Ther Targets. 2011. PMID: 21819318 Review.
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.
Zambonin V, De Toma A, Carbognin L, Nortilli R, Fiorio E, Parolin V, Pilotto S, Cuppone F, Pellini F, Lombardi D, Pollini GP, Tortora G, Bria E. Zambonin V, et al. Among authors: cuppone f. Expert Opin Biol Ther. 2017 Apr;17(4):497-506. doi: 10.1080/14712598.2017.1289171. Epub 2017 Feb 13. Expert Opin Biol Ther. 2017. PMID: 28133971 Review.
Non-small cell lung cancer: early stages.
Bria E, Ceribelli A, Trovò MG, Gelibter A, Gigante M, Calabrò E, Cuppone F, Cognetti F, Terzoli E, Pastorino U. Bria E, et al. Among authors: cuppone f. Ann Oncol. 2006 Mar;17 Suppl 2:ii17-21. doi: 10.1093/annonc/mdj913. Ann Oncol. 2006. PMID: 16608973 Free article. Review. No abstract available.
Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nisticò C, Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G. Carlini P, et al. Among authors: cuppone f. Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. doi: 10.1517/13543784.16.7.1023. Expert Opin Investig Drugs. 2007. PMID: 17594187 Review.
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
Caccese M, Ferrara R, Pilotto S, Carbognin L, Grizzi G, Caliò A, Brunelli M, Cuppone F, Petraglia S, Scarpa A, Tortora G, Bria E. Caccese M, et al. Among authors: cuppone f. Expert Opin Pharmacother. 2016 Dec;17(17):2253-2266. doi: 10.1080/14656566.2016.1242578. Epub 2016 Oct 8. Expert Opin Pharmacother. 2016. PMID: 27682212 Review.
Targeting targeted agents: open issues for clinical trial design.
Bria E, Di Maio M, Carlini P, Cuppone F, Giannarelli D, Cognetti F, Milella M. Bria E, et al. Among authors: cuppone f. J Exp Clin Cancer Res. 2009 May 22;28(1):66. doi: 10.1186/1756-9966-28-66. J Exp Clin Cancer Res. 2009. PMID: 19463172 Free PMC article. Review.
Adjuvant chemotherapy for non-small cell lung cancer.
Bria E, Cuppone F, Cecere FL, Milella M, Nisticò C, Cognetti F, Terzoli E. Bria E, et al. Among authors: cuppone f. J Thorac Oncol. 2007 May;2(5 Suppl):S7-11. doi: 10.1097/01.JTO.0000268633.87529.75. J Thorac Oncol. 2007. PMID: 17457237 Free article. Review.
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.
Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, Sperduti I, Gelibter A, Scagliotti GV, Cognetti F, Giannarelli D. Bria E, et al. Among authors: cuppone f. Ann Oncol. 2011 Oct;22(10):2277-85. doi: 10.1093/annonc/mdq742. Epub 2011 Feb 16. Ann Oncol. 2011. PMID: 21325444 Free PMC article. Review.
43 results